CT-Based Radiomics Can Predict the Efficacy of Anlotinib in Advanced Non-Small-Cell Lung Cancer

Figure 6

Kaplan–Meier survival analyses of OS between the low- and high-risk groups in the CE-CT cohort. (a) The CE radiomic only model in the internal validation set; (b) the CE radiomic only model in the external validation set; (c) the CE radiomic-combined model in the internal validation set; (d) the CE radiomic-combined model in the external validation set.

(a)

(b)

(c)

(d)